C07C309/04

SALTS OF TRANEXAMIC ACID ESTERS

Various salts of tranexamic acid esters compounds are described, along with compositions including such compounds. Methods of use for treatment of external surfaces (e.g. skin) and processes of producing the compounds and compositions are also described.

Nitrogen-containing Derivative of Substituted Phenol Hydroxy Acid Ester, and Preparation and Use Thereof
20220388947 · 2022-12-08 ·

A nitrogen-containing derivative of substituted phenol hydroxyl acid ester is represented by formula (I). A salt of the compound of formula (I) has good water solubility, and in vivo, can rapidly and completely release substituted phenols having a pharmacological effect, which can improve the water solubility of substituted phenols, rapidly exert the pharmacological effects of substituted phenols in vivo, and has good safety. The method for preparing the above-mentioned compound is provided. This compound can also be used in the preparation of drugs that produce anaesthesia and/or sedative and hypnotic effects on humans and animals.

##STR00001##

OLEFIN SULFONATES

The present disclosure is directed to surfactants (in particular olefin sulfonates), surfactant packages, compositions derived thereof, and uses thereof in hydrocarbon recovery. Methods of making olefin sulfonate surfactants are also described.

Salts and prodrugs of 1-methyl-d-tryptophan

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

Salts and prodrugs of 1-methyl-d-tryptophan

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

PROCESS FOR MANUFACTURING ALKANESULFONIC ACIDS

The present invention relates to an improved process for the production of alkanesulfonic acids.

PROCESS FOR MANUFACTURING ALKANESULFONIC ACIDS

The present invention relates to an improved process for the production of alkanesulfonic acids.

PROCESS FOR THE PRODUCTION OF ALKANESULFONIC ACIDS
20220332678 · 2022-10-20 ·

A process for the manufacturing of alkanesulfonic acid by reaction of an alkane with an anhydride in the presence of sulfuric acid and a starter at ambient temperature or higher and under pressure.